DexCom, Inc. $DXCM Position Reduced by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 17.4% in the third quarter, Holdings Channel reports. The fund owned 48,937 shares of the medical device company’s stock after selling 10,319 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in DexCom were worth $4,223,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Ascentis Independent Advisors bought a new stake in shares of DexCom during the 1st quarter valued at about $25,000. Latitude Advisors LLC purchased a new stake in shares of DexCom during the 3rd quarter valued at about $32,000. Hilton Head Capital Partners LLC lifted its stake in shares of DexCom by 242.3% in the 3rd quarter. Hilton Head Capital Partners LLC now owns 380 shares of the medical device company’s stock worth $33,000 after purchasing an additional 269 shares during the period. Wellington Grp LLC lifted its stake in shares of DexCom by 778.7% in the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after purchasing an additional 475 shares during the period. Finally, Elevation Wealth Partners LLC boosted its holdings in shares of DexCom by 61.0% in the third quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock worth $35,000 after buying an additional 152 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

DXCM has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their target price on shares of DexCom from $82.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 30th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $97.00 target price (up from $94.00) on shares of DexCom in a report on Friday, October 30th. Rothschild & Co Redburn lifted their price objective on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Truist Financial set a $102.00 target price on DexCom and gave the stock a “buy” rating in a research report on Friday, September 18th. Finally, BTIG Research increased their price objective on shares of DexCom from $90.00 to $96.00 and gave the company a “buy” rating in a research report on Monday, October 12th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, DexCom presently has a consensus rating of “Buy” and an average price target of $95.50.

DexCom Stock Performance

DXCM opened at $79.41 on Monday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.40 and a current ratio of 1.74. The stock’s 50 day moving average price is $85.21 and its 200-day moving average price is $75.01. DexCom, Inc. has a one year low of $54.11 and a one year high of $92.59. The stock has a market cap of $29.62 billion, a price-to-earnings ratio of 31.14, a P/E/G ratio of 1.31 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 29th. The medical device company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.05. The business had revenue of $1.34 billion during the quarter, compared to the consensus estimate of $1.33 billion. DexCom had a return on equity of 37.77% and a net margin of 19.42%. The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period last year, the company earned $0.61 earnings per share. On average, equities analysts forecast that DexCom, Inc. will post 2.68 EPS for the current year.

Insider Transactions at DexCom

In other news, Director Nicholas Augustinos sold 6,539 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total transaction of $549,537.56. Following the transaction, the director directly owned 29,293 shares in the company, valued at approximately $2,461,783.72. This trade represents a 18.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of the stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $85.48, for a total value of $145,316.00. Following the sale, the executive vice president directly owned 98,185 shares in the company, valued at $8,392,853.80. This trade represents a 1.70% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 22,822 shares of company stock valued at $1,920,193. Company insiders own 0.28% of the company’s stock.

About DexCom

DexCom, Inc develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions.

The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.